Yes, the pregabalin dose requires adjustment
With an eGFR of 28 mL/min/1.73 m², this patient's current dose of pregabalin 50 mg once daily is inappropriate and should be reduced to 25 mg once daily. 1
Dosing Algorithm for Renal Impairment
Pregabalin is eliminated primarily by renal excretion, making dose adjustment essential in patients with reduced kidney function 2, 1. The FDA-approved dosing table provides clear guidance based on creatinine clearance (CLcr):
Step 1: Estimate Creatinine Clearance
- Use the Cockcroft-Gault equation to estimate CLcr 1
- In this 86-year-old patient with eGFR 28 mL/min/1.73 m², the CLcr is likely in the 15-30 mL/min range (Stage 4 CKD)
Step 2: Apply FDA Dose Adjustment
For patients with CLcr 15-30 mL/min 1:
- If the normal daily dose is 150 mg/day: reduce to 25-50 mg once daily
- If the normal daily dose is 300 mg/day: reduce to 75 mg once daily
- If the normal daily dose is 600 mg/day: reduce to 150 mg once daily
Since this patient is taking 50 mg once daily (total daily dose = 50 mg), and assuming this represents a starting dose for neuropathic pain, the appropriate adjustment is 25 mg once daily 1.
Step 3: Consider Supplemental Dosing if on Hemodialysis
If this patient were on hemodialysis, an additional supplemental dose would be required immediately after each 4-hour dialysis session, as pregabalin is effectively removed by hemodialysis (approximately 50% reduction in plasma concentrations) 1, 3.
Critical Safety Considerations
Risk of Drug Accumulation
Pregabalin clearance is directly proportional to creatinine clearance (56-58% correlation) 3. Without dose adjustment, this patient faces:
- Increased AUC and prolonged half-life 3
- Dose-dependent adverse effects including dizziness, somnolence, peripheral edema, balance disorder, asthenia, and constipation 2, 4
- In elderly patients (≥65 years), neurological adverse reactions are more frequent: dizziness, blurred vision, balance disorder, tremor, confusion, coordination abnormalities, and lethargy 1
Elderly-Specific Concerns
At 86 years old, this patient requires particular caution 2:
- Start with lower doses and titrate slowly in geriatric patients 2
- Pregabalin clearance decreases with age due to age-related decline in renal function 1
- The risk of falls and cognitive impairment increases with standard dosing
Withdrawal Risk
Never abruptly discontinue pregabalin, even in renal impairment. A case report documented a tonic-clonic seizure in a patient with CKD (eGFR 15 mL/min) whose pregabalin was suddenly stopped during acute illness 5. If dose reduction is needed, taper gradually.
Monitoring and Titration
After dose adjustment to 25 mg once daily:
- Monitor for symptom control (pain relief or seizure control, depending on indication)
- Assess for adverse effects, particularly neurological symptoms and peripheral edema
- If pain control is inadequate after 1-2 weeks and the medication is well-tolerated, may cautiously increase to 50 mg once daily (the current dose)
- Maximum recommended dose for CLcr 15-30 mL/min is typically 75 mg once daily 1
Common Pitfall
The most common error is using eGFR directly from laboratory reports instead of calculating CLcr using Cockcroft-Gault 1. While recent guidelines suggest race-free eGFR for CKD staging 6, the FDA label for pregabalin specifically requires Cockcroft-Gault CLcr for dosing decisions 1. In elderly patients with low muscle mass, serum creatinine may appear normal despite significant renal impairment, making calculation essential 7, 8.